Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.
UNLABELLED: Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatoce...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
2014
|
| _version_ | 1826293829348622336 |
|---|---|
| author | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjaer, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D |
| author_facet | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjaer, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D |
| author_sort | Aleksandrova, K |
| collection | OXFORD |
| description | UNLABELLED: Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations=1.22; 95% CI=1.02-1.46; P=0.03; 1.90; 95% CI=1.30-2.77; P=0.001; 2.25; 95% CI=1.43-3.54; P=0.0005; and 2.09; 95% CI=1.19-3.67; P=0.01, respectively). CRP was associated also with risk of GBTC (IRR=1.22; 95% CI=1.05-1.42; P=0.01). GLDH was associated with risks of HCC (IRR=1.62; 95% CI=1.25-2.11; P=0.0003) and IBD (IRR=10.5; 95% CI=2.20-50.90; P=0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. CONCLUSION: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. |
| first_indexed | 2024-03-07T03:36:12Z |
| format | Journal article |
| id | oxford-uuid:bc5f910e-b9be-4ed7-b681-38b8f2c7c6e7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:36:12Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:bc5f910e-b9be-4ed7-b681-38b8f2c7c6e72022-03-27T05:23:59ZInflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bc5f910e-b9be-4ed7-b681-38b8f2c7c6e7EnglishSymplectic Elements at Oxford2014Aleksandrova, KBoeing, HNöthlings, UJenab, MFedirko, VKaaks, RLukanova, ATrichopoulou, ATrichopoulos, DBoffetta, PTrepo, EWesthpal, SDuarte-Salles, TStepien, MOvervad, KTjønneland, AHalkjaer, JBoutron-Ruault, MDossus, LRacine, ALagiou, PBamia, CBenetou, VAgnoli, CPalli, DUNLABELLED: Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations=1.22; 95% CI=1.02-1.46; P=0.03; 1.90; 95% CI=1.30-2.77; P=0.001; 2.25; 95% CI=1.43-3.54; P=0.0005; and 2.09; 95% CI=1.19-3.67; P=0.01, respectively). CRP was associated also with risk of GBTC (IRR=1.22; 95% CI=1.05-1.42; P=0.01). GLDH was associated with risks of HCC (IRR=1.62; 95% CI=1.25-2.11; P=0.0003) and IBD (IRR=10.5; 95% CI=2.20-50.90; P=0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. CONCLUSION: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. |
| spellingShingle | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjaer, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title_full | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title_fullStr | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title_full_unstemmed | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title_short | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. |
| title_sort | inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| work_keys_str_mv | AT aleksandrovak inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boeingh inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT nothlingsu inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT jenabm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT fedirkov inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT kaaksr inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT lukanovaa inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trichopouloua inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trichopoulosd inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boffettap inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trepoe inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT westhpals inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT duartesallest inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT stepienm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT overvadk inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT tjønnelanda inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT halkjaerj inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boutronruaultm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT dossusl inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT racinea inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT lagioup inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT bamiac inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT benetouv inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT agnolic inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT pallid inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer |